Replies to post #185916 on Biotech Values

[xavierprivas]

I don't think it is justified. OnCore drugs are all preclinical, not
even p1. Lots of stuff sound good on paper or in test tube, but HBV
is a tough nut to crack. I wait it out until there is some evidence
that this combo approach is working, there is plenty of time.